Vortioxetine vs. Bupropion (Wellbutrin): Side Effect Profile Comparison
Vortioxetine and bupropion have distinctly different side effect profiles: vortioxetine primarily causes gastrointestinal symptoms (especially nausea) and carries typical SSRI-related sexual dysfunction, while bupropion has minimal sexual side effects but carries seizure risk and more activating symptoms like agitation and insomnia.
Key Distinguishing Features
Sexual Dysfunction
The most clinically significant difference is sexual side effects. Bupropion has a significantly lower rate of sexual adverse events compared to SSRIs like fluoxetine and sertraline 1. This advantage extends to comparisons with vortioxetine, which as a serotonergic agent causes sexual dysfunction in a substantial proportion of patients 2. In fact, switching to vortioxetine from other antidepressants specifically for sexual dysfunction showed improvement in 83.81% of patients 2, but this reflects improvement from other SSRIs, not from bupropion.
Gastrointestinal Effects
Vortioxetine's most common adverse effect is nausea 3, 4, 5, followed by vomiting, diarrhea, and constipation 4, 5. This nausea can be particularly problematic in cancer patients receiving chemotherapy 6. The FDA label confirms nausea as the predominant side effect 3.
Bupropion causes less gastrointestinal distress overall, though nausea and vomiting can occur and were among the most common reasons for discontinuation in efficacy studies 7.
Neuropsychiatric and Activating Effects
Bupropion carries a dose-dependent seizure risk, with weak evidence indicating an increased association 1. The FDA label specifies bupropion is contraindicated in patients with seizure disorders, brain metastases, or stroke history 6, 7. Maximum dosing is limited to 450 mg/day for immediate-release and 400 mg/day for sustained-release formulations to minimize seizure risk 8.
Bupropion also causes more activating symptoms including:
- Agitation (1.8% at 400 mg/day vs. 0.3% placebo) 7
- Insomnia (13-20% in clinical trials) 7
- Tremor (6% at 300 mg/day) 7
- Anxiety and nervousness 7
Vortioxetine causes less activation but can produce insomnia, anxiety, and abnormal dreams 3. Both medications carry black box warnings for neuropsychiatric effects including depression and suicidal ideation, though a large RCT found no significant increase in neuropsychiatric adverse events with either medication compared to placebo 6.
Weight and Metabolic Effects
Bupropion is associated with weight loss rather than weight gain—14-23% of patients lost >5 lbs in clinical trials 7. This contrasts with many antidepressants that cause weight gain 1.
Vortioxetine appears weight-neutral based on available data 3, 4.
Cardiovascular Effects
Vortioxetine can cause hypertension (2% vs. 0% placebo) 3 and tinnitus (3% vs. <1% placebo) 3. The FDA label notes no significant QTc prolongation at therapeutic or supratherapeutic doses 3.
Bupropion has weak evidence for cardiovascular risks 1, though this is less prominent than with venlafaxine.
Tolerability and Discontinuation
Vortioxetine demonstrates better overall tolerability. In switching studies, vortioxetine had statistically significantly lower withdrawal rates due to adverse events compared to sertraline (12.1% difference), venlafaxine XR (12.3% difference), and bupropion SR (18.3% difference) 9.
The sustained-release formulation of bupropion has fewer side effects than immediate-release, with substantially lower seizure incidence 10.
Clinical Decision Algorithm
Choose bupropion when:
- Sexual dysfunction is a primary concern or previous issue
- Patient needs weight loss or weight neutrality
- Comorbid ADHD symptoms present
- Smoking cessation is a goal 8
Avoid bupropion in:
- Seizure history or risk factors (brain metastases, stroke, eating disorders)
- Concurrent MAO inhibitor use
- Patients taking tamoxifen
- Closed-angle glaucoma 6
Choose vortioxetine when:
- Cognitive symptoms are prominent (memory, executive function) 5
- Patient has failed SSRI/SNRI therapy 9, 11
- Anxiety is a prominent comorbid feature 4
- Seizure risk factors present
Avoid vortioxetine in:
- Patients intolerant of nausea (especially during chemotherapy)
- When sexual function is a priority concern
- Patients requiring rapid dose escalation (nausea worsens with faster titration)
Common Pitfalls
The most common error is assuming vortioxetine has minimal sexual side effects because it's "different" from SSRIs—it remains a serotonergic agent and causes sexual dysfunction, just potentially less than traditional SSRIs 2. The second pitfall is underestimating bupropion's seizure risk, particularly when combining with other seizure-lowering medications or in patients with eating disorders where electrolyte abnormalities increase risk.